Top Isotretinoin Brands You Should Know for Clearer Skin

Navigating the world of skincare treatments can be overwhelming, especially when it comes to finding effective solutions for severe acne. Isotretinoin, a potent oral medication, has become a game-changer in treating this persistent condition, with several reputable brands leading the charge. While Accutane is among the most well-known, brands like Claravis, Amnesteem, and Myorisan have also established themselves as trusted options for consumers seeking relief. To help you make an informed choice, we've compiled a comprehensive list of the best isotretinoin brands available on the market today.

Illustration of isotretinoin

Best brands of isotretinoin in 2025

Accutane

Accutane, a brand name for isotretinoin, is a highly effective treatment for severe acne, with over 95% of patients experiencing no further acne breakouts after completing the typical 20-week course. It is an FDA-approved, vitamin A derivative that inhibits sebaceous gland function and keratinization, making it a gold standard for treating recalcitrant acne. Introduced by Roche Pharmaceuticals, Accutane was initially discontinued in 2002 but is now available through generic versions and other brand names like Absorica, Amnesteem, and Zenatane. The drug is strictly monitored through the iPLEDGE program to prevent birth defects and ensure proper use. Accutane is prescribed by board-certified dermatologists and requires monthly visits and blood tests to monitor side effects. For more detailed information about Accutane treatment for acne, visit their website.

Claravis

Claravis, a prominent brand of isotretinoin, is highly regarded for its effectiveness in treating severe recalcitrant nodular acne. Since the original manufacturer of Accutane, Roche Pharmaceuticals, ceased production in 2009, Claravis has become one of the leading branded generics available. It is a synthetic retinoid closely related to Vitamin A, dramatically reducing the production of natural oil in the skin and preventing clogged pores, with millions of users worldwide benefiting from its treatment since its introduction. For further details on Claravis, you can visit the DailyMed website.

Absorica

Absorica, a brand of isotretinoin, is a leading treatment for severe nodular acne that has not responded to other treatments, including antibiotics. It is available only from certified pharmacies under the iPLEDGE program due to its potential side effects. In 2021, the U.S. isotretinoin prescription market, which includes Absorica, saw an 18.2% increase, contributing to significant revenue growth for its manufacturers. Absorica LD, a micronized formulation of isotretinoin, is offered in various strengths (8 mg, 16 mg, 24 mg, and 32 mg) and is distributed by Sun Pharma Canada Inc. The market share of Absorica and its authorized generic version was approximately 6.2% in the second quarter of 2021. For more information, visit their detailed product page.

Roaccutane

Roaccutane, a brand name for isotretinoin, is a highly effective prescription-only medication for severe acne and other similar skin conditions, having been available for over 40 years. It is typically prescribed by experienced dermatologists due to its potent effects, including reducing sebum production by up to 90% and inducing apoptosis in sebaceous gland cells. The global isotretinoin market, which includes Roaccutane, was valued at USD 1,337 million in 2022 and is expected to grow at a CAGR of 4.88% until 2031. Roaccutane is usually administered in capsule form and is known for its efficacy in treating moderate to severe acne, with retinoids like isotretinoin dominating about 29% of the acne medication market. The medication's absorption is enhanced when taken with a high-fat meal, reaching maximum concentrations within 1-4 hours. For more information on isotretinoin and Roaccutane, visit Skindoc's detailed Isotretinoin page.

Amnesteem

Amnesteem, a brand of isotretinoin, is a highly effective treatment for severe nodular acne, particularly for cases that have not responded to other treatments, including antibiotics. Marketed by Bertek Pharmaceuticals Inc., Amnesteem is bioequivalent to Roche Laboratories' Accutane and is available in 10 mg, 20 mg, and 40 mg strengths. The drug is part of a special program called iPLEDGE due to its high risk of severe birth defects if taken during pregnancy. Amnesteem has been a significant player in the isotretinoin market, which is projected to grow at a CAGR of 4.88% from 2023 to 2031, with the global market size estimated to reach USD 2,053 million by 2031. The drug's efficacy and strict regulatory oversight ensure its safe and effective use. For more detailed information, visit their official page on Drugs.com.

Zenatane

Zenatane, a generic version of Hoffman LaRoche's Accutane, is a leading brand in the isotretinoin market, renowned for its effectiveness in treating severe recalcitrant nodular acne. Available in strengths of 10 mg, 20 mg, 30 mg, and 40 mg, it was re-launched in the US market by Dr. Reddy's Laboratories in 2019, achieving US sales of approximately $525 million in the preceding 12 months. Zenatane must be prescribed and dispensed under the iPLEDGE program due to its teratogenicity. The product is highly regarded for its ability to reduce natural oil production and prevent clogged pores, making it a compelling treatment for severe acne. Its launch has significantly impacted the market, providing essential access to this medicine for patients. Find more information about Zenatane here.

Myorisan

Myorisan, a brand of isotretinoin capsules, stands as a leading treatment for severe recalcitrant nodular acne, available in 10-mg, 20-mg, 30-mg, and 40-mg soft gelatin capsules. It is part of a special restricted distribution program approved by the FDA, known as the iPLEDGE program, designed to minimize fetal exposure due to its teratogenicity. Myorisan must be prescribed and dispensed by registered and activated prescribers and pharmacies, respectively, and patients must also be registered with the iPLEDGE program. The isotretinoin drug market, including Myorisan, is projected to grow at a CAGR of around 4.88% from 2023 to 2031, fueled by the rising prevalence of acne in young adults and teens. Approved by the FDA on April 30, 2012, Myorisan is manufactured by VersaPharm, Inc. For more detailed information, visit the Myorisan drug page.

Epuris

Epuris, a brand of isotretinoin, is distinguished by its high bioavailability and reliable absorption, making it a preferred choice for treating severe acne. It achieved a significant market share of approximately 43% in Canada as of June 2021. Epuris capsules are available in strengths of 10, 20, 30, and 40 mg and are noted for their improved absorption even under varying dietary conditions, being 83% more bioavailable than Accutane when taken without food. This product is administered orally, typically once or twice daily, for a treatment period of about five months. Its efficacy and bioavailability have contributed to its strong market presence and revenue growth. For more detailed information, visit the Epuris product page.

Isotroin

Isotretinoin, a potent retinoid used primarily for severe acne, is produced by several leading pharmaceutical companies, with Amneal Pharmaceuticals being a notable player. Amneal introduced its generic isotretinoin capsules in 2018, which are available in strengths of 10 mg, 20 mg, 30 mg, and 40 mg, and are part of the iPledge program to ensure safe use. The global isotretinoin market is expected to grow significantly, with a projected CAGR of 10.6% from 2024 to 2030, reaching a market size of $1.726 billion by 2030. Major companies like Amneal, Teva, and Sun Pharmaceutical are driving this growth through their high-quality and affordable products. The market's expansion is fueled by increasing awareness of skincare, technological advancements, and the prevalence of severe acne.

Sotret

Sotret, a brand of isotretinoin, is a leading product in the market, known for its strict distribution program, iPLEDGE, to minimize fetal exposure due to its teratogenicity. It is available in 10 mg, 20 mg, 30 mg, and 40 mg soft gelatin capsules and must be prescribed and dispensed by registered and activated healthcare providers and pharmacies. The global isotretinoin market, which includes Sotret, is projected to grow at a CAGR of 4.88% from 2023 to 2031, reaching USD 2,053 million by 2031. Sotret is manufactured by Ranbaxy Laboratories Inc. and is part of a market dominated by North America, with a significant presence in Europe and the Asia-Pacific region. The product's efficacy in treating severe inflammatory acne and other skin disorders has made it a crucial component in dermatological treatments. For more information, visit the official DailyMed Sotret information page.